{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:24:04Z","timestamp":1789219444692,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["P01 AG078106"],"award-info":[{"award-number":["P01 AG078106"]}]},{"DOI":"10.13039\/100032490","name":"Freedom Together Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032490","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BrightFocus Foundation grant","award":["A2022051S"],"award-info":[{"award-number":["A2022051S"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are no available treatments to halt or slow the progression of cerebral amyloid angiopathy (CAA), a disease neuropathologically characterized by the deposition of amyloid-\u03b2 (A\u03b2) within the walls of the cerebrovasculature. Recently a novel therapeutic strategy has been described, targeting non-lipidated ApoE4 that co-deposits with A\u03b2, resulting in lower levels of A\u03b2 across the brain. To understand the therapeutic potential for patients with CAA, we sought to determine if this global reduction in A\u03b2 deposits corresponds to the active removal of existing aggregates in the vasculature and if so, whether this may improve vascular function over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cranial windows were implanted in 9-10-month-old 5xFAD mice expressing human APOE4 to facilitate chronic, unanesthetized imaging using in vivo multiphoton microscopy. Mice were treated weekly with anti-ApoE4 immunotherapy (HAE-4) or control IgG (50\u00a0mg\/kg). Parenchymal and vascular A\u03b2 burden as well as vascular function were measured in vivo before and during treatment. Post-mortem brains were assessed for CAA, parenchymal A\u03b2 plaques and iron deposits. In a separate study, 5xFAD mice were treated with weekly HAE-4 or control IgG with the same doses of antibodies from 8 to 10 months of age in the absence of cranial windows.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment with HAE-4 resulted in reduction of total A\u03b2 plaque area post-mortem in mice and shrinkage of existing smaller plaques imaged with in vivo multiphoton microscopy. Vascular fibrillar A\u03b2 under the cranial window conversely increased over time either with or without HAE-4 treatment and there was no treatment-associated improvement in vascular function in cortical arterioles in the areas measured in vivo. There was no evidence of hemorrhagic events linked to treatment, however there was significant immune cell activation. In 5xFAD mice treated without a cranial window, there was a reduction in plaques and CAA as previously described in HAE-4 vs. control treated mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti-ApoE4 immunotherapy, as shown previously, decreased the overall amount of A\u03b2. It also appeared to remove some existing plaque A\u03b2 without measurable effects on vascular fibrillar A\u03b2 deposits or vascular function in areas measured in vivo under a cranial window. The absence of treatment-associated hemorrhagic events may offer a comparative advantage relative to anti-A\u03b2 immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-026-00957-x","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:07:39Z","timestamp":1781197659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal multiphoton imaging of cerebral amyloid angiopathy in response to anti-ApoE4 immunotherapy in mice"],"prefix":"10.1186","volume":"21","author":[{"given":"Orla","family":"Bonnar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareeha","family":"Saadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Sanchez-Mico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee H.","family":"Hanlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali A.","family":"Vom Eigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mumbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Bacskai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne J.","family":"van Veluw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"957_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease \u2014 one peptide, two pathways. Nat Rev Neurol. 2020;16:30\u201342.","journal-title":"Nat Rev Neurol"},{"key":"957_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/alz.12366","volume":"18","author":"L J\u00e4kel","year":"2022","unstructured":"J\u00e4kel L, De Kort AM, Klijn CJM, Schreuder FHBM, Verbeek MM. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimer\u2019s Dement. 2022;18:10\u201328.","journal-title":"Alzheimer\u2019s Dement"},{"key":"957_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"957_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","volume":"21","author":"SM Greenberg","year":"2025","unstructured":"Greenberg SM, Bax F, van Veluw SJ. Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms. Nat Rev Neurol. 2025;21:193\u2013203.","journal-title":"Nat Rev Neurol"},{"key":"957_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S1474-4422(21)00213-1","volume":"20","author":"SM Greenberg","year":"2021","unstructured":"Greenberg SM, Cordonnier C, Schneider JA, Smith EE, van Buchem MA, van Veluw SJ, et al. Off-label use of aducanumab for cerebral amyloid angiopathy. Lancet Neurol. 2021;20:596\u20137.","journal-title":"Lancet Neurol"},{"key":"957_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022;79:13\u201321.","journal-title":"JAMA Neurol"},{"key":"957_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1161\/01.STR.27.8.1333","volume":"27","author":"SM Greenberg","year":"1996","unstructured":"Greenberg SM, Briggs ME, Hyman BT, Kokoris GJ, Takis C, Kanter DS, et al. Apolipoprotein E \u03b54 Is Associated With the Presence and Earlier Onset of Hemorrhage in Cerebral Amyloid Angiopathy. Stroke. 1996;27:1333\u20137.","journal-title":"Stroke"},{"key":"957_CR8","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1523\/JNEUROSCI.5170-04.2005","volume":"25","author":"JD Fryer","year":"2005","unstructured":"Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, et al. Human Apolipoprotein E4 Alters the Amyloid-\u03b2 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model. J Neurosci. 2005;25:2803\u201310.","journal-title":"J Neurosci"},{"key":"957_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/NEN.0b013e31829a25b9","volume":"72","author":"PT Nelson","year":"2013","unstructured":"Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, et al. APOE-\u03b52 and APOE-\u03b54 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72:708\u201315.","journal-title":"J Neuropathol Exp Neurol"},{"key":"957_CR10","doi-asserted-by":"publisher","first-page":"eabd7522","DOI":"10.1126\/scitranslmed.abd7522","volume":"13","author":"M Xiong","year":"2021","unstructured":"Xiong M, Jiang H, Serrano JR, Gonzales ER, Wang C, Gratuze M, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. 2021;13:eabd7522.","journal-title":"Sci Transl Med"},{"key":"957_CR11","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1172\/JCI96429","volume":"128","author":"F Liao","year":"2018","unstructured":"Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest. 2018;128:2144\u201355.","journal-title":"J Clin Invest"},{"key":"957_CR12","doi-asserted-by":"crossref","unstructured":"Huynh TPV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM et al. Lack of hepatic apoE does not influence early A\u03b2 deposition: observations from a new APOE knock-in model. Mol Neurodegener. 2019;14.","DOI":"10.1186\/s13024-019-0337-1"},{"key":"957_CR13","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1016\/j.neuron.2025.08.008","volume":"113","author":"F Saadi","year":"2025","unstructured":"Saadi F, Katritch IV, Parhizkar S, Lugo B, Cho Y, Ulrich JD, et al. Maternal Inheritance Suppresses CAA and Amyloid Plaques in 5xFAD (Tg7031)\/APOE4 Mice. Neuron. 2025;113:2883.","journal-title":"Neuron"},{"key":"957_CR14","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1177\/0271678X231152550","volume":"43","author":"LP Munting","year":"2023","unstructured":"Munting LP, Bonnar O, Kozberg MG, Auger CA, Hirschler L, Hou SS, et al. Spontaneous vasomotion propagates along pial arterioles in the awake mouse brain like stimulus-evoked vascular reactivity. J Cereb Blood Flow Metab. 2023;43:1752\u201363.","journal-title":"J Cereb Blood Flow Metab"},{"key":"957_CR15","doi-asserted-by":"crossref","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al. Fiji: an open-source platform for biological-image analysis. Nature Methods. 2012;9:676\u201382.","DOI":"10.1038\/nmeth.2019"},{"key":"957_CR16","first-page":"1","volume":"2017 7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;2017 7:1.","journal-title":"Sci Rep"},{"key":"957_CR17","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2022."},{"key":"957_CR18","doi-asserted-by":"crossref","unstructured":"Kozberg MG, Munting LP, Hanlin LH, Auger CA, van den Berg ML, Denis, de Senneville B et al. Vasomotion loss precedes impaired cerebrovascular reactivity and microbleeds in cerebral amyloid angiopathy. Brain Commun. 2025;7:fcaf186.","DOI":"10.1093\/braincomms\/fcaf186"},{"key":"957_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1474-4422(23)00114-X","volume":"22","author":"EA Koemans","year":"2023","unstructured":"Koemans EA, Chhatwal JP, van Veluw SJ, van Etten ES, van Osch MJP, van Walderveen MAA, et al. Progression of cerebral amyloid angiopathy: a pathophysiological framework. Lancet Neurol. 2023;22:632\u201342.","journal-title":"Lancet Neurol"},{"key":"957_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.neuron.2019.10.033","volume":"105","author":"SJ van Veluw","year":"2020","unstructured":"van Veluw SJ, Hou SS, Calvo-Rodriguez M, Arbel-Ornath M, Snyder AC, Frosch MP, et al. Vasomotion as a Driving Force for Paravascular Clearance in the Awake Mouse Brain. Neuron. 2020;105:549\u201361.","journal-title":"Neuron"},{"key":"957_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1474-4422(16)30346-5","volume":"16","author":"AM van Opstal","year":"2017","unstructured":"van Opstal AM, van Rooden S, van Harten T, Ghariq E, Labadie G, Fotiadis P, et al. Cerebrovascular function in presymptomatic and symptomatic individuals with hereditary cerebral amyloid angiopathy: a case-control study. Lancet Neurol. 2017;16:115\u201322.","journal-title":"Lancet Neurol"},{"key":"957_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, Noristani HN, Fitzgerald GJ, Oluoch H, Babb N, McGathey T, et al. Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2024;19:77.","journal-title":"Mol Neurodegener"},{"key":"957_CR23","doi-asserted-by":"publisher","first-page":"fcac245","DOI":"10.1093\/braincomms\/fcac245","volume":"4","author":"MG Kozberg","year":"2022","unstructured":"Kozberg MG, Yi I, Freeze WM, Auger CA, Scherlek AA, Greenberg SM, et al. Blood-brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy. Brain Commun. 2022;4:fcac245.","journal-title":"Brain Commun"},{"key":"957_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.nicl.2016.02.020","volume":"11","author":"AR Switzer","year":"2016","unstructured":"Switzer AR, McCreary C, Batool S, Stafford RB, Frayne R, Goodyear BG, et al. Longitudinal decrease in blood oxygenation level dependent response in cerebral amyloid angiopathy. Neuroimage Clin. 2016;11:461\u20137.","journal-title":"Neuroimage Clin"},{"key":"957_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/acn3.761","volume":"6","author":"C Leurent","year":"2019","unstructured":"Leurent C, Goodman JA, Zhang Y, He P, Polimeni JR, Gurol ME, et al. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. Ann Clin Transl Neurol. 2019;6:795\u2013806.","journal-title":"Ann Clin Transl Neurol"},{"key":"957_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1098\/rstb.2015.0348","volume":"371","author":"CN Hall","year":"2016","unstructured":"Hall CN, Howarth C, Kurth-Nelson Z, Mishra A. Interpreting bold: Towards a dialogue between cognitive and cellular neuroscience. Philosophical Trans Royal Soc B: Biol Sci. 2016;371:1\u201312.","journal-title":"Philosophical Trans Royal Soc B: Biol Sci"},{"key":"957_CR27","doi-asserted-by":"publisher","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","volume":"36","author":"KV Kastanenka","year":"2016","unstructured":"Kastanenka KV, Bussiere T, Shakerdge N, Qian F, Weinreb PH, Rhodes K, et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. J Neurosci. 2016;36:12549\u201358.","journal-title":"J Neurosci"},{"key":"957_CR28","doi-asserted-by":"publisher","first-page":"147ra111","DOI":"10.1126\/scitranslmed.3003748","volume":"4","author":"JJ Iliff","year":"2012","unstructured":"Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2. Sci Transl Med. 2012;4:147ra111.","journal-title":"Sci Transl Med"},{"key":"957_CR29","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41593-023-01327-2","volume":"26","author":"S Holstein-R\u00f8nsbo","year":"2023","unstructured":"Holstein-R\u00f8nsbo S, Gan Y, Giannetto MJ, Kaag Rasmussen M, Sigurdsson B, Ralf M, Beinlich F, et al. Glymphatic influx and clearance are accelerated by neurovascular coupling Check for updates. Nat Neurosci |. 2023;26:1042\u201353.","journal-title":"Nat Neurosci |"},{"key":"957_CR30","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1038\/s41467-021-23508-y","volume":"12","author":"K Shaw","year":"2021","unstructured":"Shaw K, Bell L, Boyd K, Grijseels DM, Clarke D, Bonnar O, et al. Neurovascular coupling and oxygenation are decreased in hippocampus compared to neocortex because of microvascular differences. Nat Commun. 2021;12:3190.","journal-title":"Nat Commun"},{"key":"957_CR31","doi-asserted-by":"publisher","first-page":"eads3204","DOI":"10.1126\/science.ads3204","volume":"389","author":"ME Pizzo","year":"2025","unstructured":"Pizzo ME, Plowey ED, Khoury N, Kwan W, Abettan J, DeVos SL, et al. Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science. 2025;389:eads3204.","journal-title":"Science"},{"key":"957_CR32","doi-asserted-by":"publisher","first-page":"e68242","DOI":"10.7554\/eLife.68242","volume":"11","author":"O Shabir","year":"2022","unstructured":"Shabir O, Pendry B, Lee L, Eyre B, Sharp PS, Rebollar MA, et al. Assessment of neurovascular coupling and cortical spreading depression in mixed mouse models of atherosclerosis and Alzheimer\u2019s disease. Elife. 2022;11:e68242.","journal-title":"Elife"},{"key":"957_CR33","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","volume":"21","author":"A Charidimou","year":"2022","unstructured":"Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF, et al. The Boston Criteria v2.0 for cerebral amyloid angiopathy: A multicentre MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21:714.","journal-title":"Lancet Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-026-00957-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00957-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00957-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:30:46Z","timestamp":1787099446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-026-00957-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1186\/s13024-026-00957-x","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were performed with the approval of the Massachusetts General Hospital (MGH) Animal Care and Use Committee and in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The lab of SJvV and OB receives additional funding from the NIH, the AHA, and the Leducq Foundation. They also receive industry support from Sanofi and Therini Bio. DMH is an inventor on US patent 11,124,562 entitled \u201cAPOE antibodies\u201d. This patent has been licensed by Washington University to NextCure.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"49"}}